Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88

Leerink Partners analyst Thomas Smith has maintained an 'Outperform' rating on Celldex Therapeutics (NASDAQ: CLDX) and raised the price target from $70 to $88. This adjustment reflects a positive outlook for the company's performance in the market.